What the Purdue Pharma Settlement Means for Delaware
Delaware made a deliberate choice to prioritize certainty over speculation—securing guaranteed, upfront funding that allows us to invest not just in immediate recovery efforts, but in sustainable, long-term solutions to the opioid crisis. This settlement is not the end of the work; it is the foundation for the next decade of it.
The headlines surrounding Purdue Pharma and the Sackler family have been a fixture of the national news for years. Following long-awaited legal developments and the resolution of complex criminal and civil proceedings, we finally have clarity on what this means for our state.
As the Director of the Delaware Opioid Settlement Commission (DOSC), I am pleased to share that Delaware is set to receive approximately $27 million from this settlement. This marks the end of a very long legal chapter. For the Commission though, it marks the beginning of a strategic opportunity to sustain our work for years to come.
Why Certainty Matters
In the settlement process, Delaware made a deliberate, strategic choice: we opted for a lower settlement amount in exchange for a guaranteed, upfront payment. In the world of bankruptcy and massive multi-district litigation, being at the front of the line matters. By choosing this path, we ensured two things:
Security: We secured our funds immediately, ensuring Delaware’s recovery efforts wouldn't be sidelined or diminished in a long list of competing creditors.
Growth: Receiving the $27 million upfront allows the Commission to put that money to work immediately—not just through grants, but through smart fiscal management.
The Long Game
You might be asking yourself—or hearing others ask—“Why not distribute all of the money right away?” It’s a fair and understandable question. Our communities are facing urgent needs, and there is a natural desire to get resources as quickly as possible to the people and programs working to save lives.
At the same time, we have to balance that urgency with sustainability. Simply spending more money faster doesn't always lead to better results, especially if programs aren't given the structure and long-term support they need to actually work. The opioid epidemic is an evolving crisis that won’t be solved by a one-time influx of cash. To avoid a “funding cliff”—where vital programs launch with fanfare but collapse the moment the money runs out—we have to be disciplined.
A Strategic Legal Foundation
This discipline is only possible because of the strategic groundwork laid by our legal partners. It is important to recognize that the ability to even have these funds today is thanks to the
persistence of Attorney General Kathy Jennings and the Delaware Department of Justice (DOJ). Her team of attorneys fought a years-long battle to ensure Delaware wasn't just another name on a list of creditors. By securing a guaranteed, upfront payment, they provided the Commission with the stability we need to plan for the next decade, rather than waiting on uncertain future installments.
Maximizing Impact Through Stewardship
Because the DOJ secured these funds upfront, we can take full advantage of current interest rates, which hover around 5%. This allows the settlement pot to grow even as we draw from it to fund active projects. Careful balancing of our grant-making, together with this interest-bearing strategy, can allow these resources last well beyond the ten years remaining on our scheduled settlement receipts.
A “big-ticket” investment may sound worthwhile, but such a move requires a foundation of evidence and data. We need the time to bring all stakeholders to the table and ensure that any massive investment is not just impactful today, but sustainable long after these settlement funds have been fully distributed. Stewardship is about more than spending; it is about ensuring the infrastructure we build now doesn’t crumble tomorrow. Thanks to the Delaware DOJ’s legal persistence and the Commission’s oversight, we have the reliable, decade-long resources needed to build the future of recovery in our state.